FB102 versus placebo for adults with celiac disease after a gluten challenge
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of FB102 in Adult Participants With Celiac Disease on a Gluten Free Diet
Run by Forte Biosciences, Inc. · NCT06982963 · Data updated 2026-11-12
This will test whether taking FB102 can prevent symptoms and immune reactions in adults with well-controlled celiac disease after a planned small gluten challenge.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Forte Biosciences, Inc. Industry-sponsored |
| Locations | 1 site (Melbourne) |
| Status | Recruiting |
| Started | August 4, 2025 |
| Main results expected | February 28, 2027 |
| Study ends | February 28, 2027 |
| Registry record updated | November 18, 2025 |
| Trial ID | NCT06982963 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults age 18–70 with biopsy-confirmed celiac disease who have followed a strict gluten-free diet for at least 12 months, have BMI 16–40 kg/m2, and are willing to undergo a brief controlled gluten challenge are ideal candidates.
✕Probably not a fit
People with uncontrolled or active celiac disease or those with neuropsychiatric problems related to gluten exposure are unlikely to benefit or may be excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, double-blind, placebo-controlled Phase 2 trial testing FB102 in adults with biopsy-confirmed celiac disease who have been on a strict gluten-free diet. Participants will be randomly assigned to receive FB102 or placebo and then undergo a controlled oral gluten challenge while remaining on their gluten-free diet otherwise. The study will measure clinical symptoms, safety, pharmacokinetics, and pharmacodynamic markers of immune response following the gluten exposure. Results will help determine whether FB102 reduces gluten-triggered intestinal and symptom responses compared with placebo.
Why it matters
Potential benefit: If successful, FB102 could reduce symptoms and immune damage after accidental or small gluten exposures for people with celiac disease.
How similar studies have gone: Some early-phase programs targeting gluten degradation or immune modulation in celiac disease have shown promise, but there are no widely approved drugs yet to prevent gluten-triggered damage.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Men and women aged 18 to 70 years at Screening. 2. Has documented diagnosis of CeD confirmed by intestinal biopsy and positive celiac serology at least 12 months prior to Screening (intestinal biopsy and serology do not have to be performed concurrently). 3. Body mass index (BMI) between 16.0 and 40.0 kg/m2, inclusive. 4. Self-reported to be on a GFD for at least 12 months prior to Screening and must be willing to remain on a GFD for the duration of study participation, with the exception of the oral gluten challenge administered as a study procedure. Prior acute and resolved accidental exposures are not exclusionary. Exclusion Criteria: 1. Uncontrolled CeD and/or active signs/symptoms of CeD, in the opinion of the Investigator. 2. History of or current neuropsychiatric manifestations specifically related to gluten exposure including ataxia, seizures, severe peripheral neuropathy, cognitive impairment, and depression.
Where it's running
-
The Royal Melbourne Hospital
Melbourne, Australia Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mediterranean diet and processed food in adults with celiac disease on a gluten-free diet
This observational study looks at whether following a Mediterranean-style diet or eating more highly processed foods affects GI symptoms and quality of life in adults with celiac disease who have been on a strict gluten-free diet.
-
Exercise for Metabolic Syndrome and Fatty Liver in Adolescent Girls with Celiac Disease
This study tests whether a 3-month walking program helps improve metabolic syndrome and fatty liver in adolescent females with celiac disease.
-
Nutrition and physical activity education for children with celiac disease
This study tests whether a combined nutrition and physical activity education program helps 8- to 12-year-olds with celiac disease improve body health, eating habits, activity, and quality of life while on a gluten-free diet.
-
Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity
This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.
-
Omega-3 fats to reduce inflammation in adults with newly diagnosed celiac disease
This study tests whether adding omega-3 fatty acid supplements to a gluten-free plan helps reduce inflammation and promote intestinal healing in adults who have just been diagnosed with celiac disease.
-
Wheat sensitivity or IBS/functional dyspepsia in relatives of people with celiac disease
This project will test whether adults related to celiac patients have higher rates of non-celiac wheat sensitivity or IBS/functional dyspepsia and whether symptoms change on a wheat-free diet.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.